Full-Time

Automation Engineer

Deadline 8/18/27
Ajinomoto Health & Nutrition North America

Ajinomoto Health & Nutrition North America

Compensation Overview

$105k - $135k/yr

+ Annual Bonus Opportunity

Raleigh, NC, USA

In Person

Associate's

Category
Electrical Engineering (1)
Required Skills
PLC
Requirements
  • An associate degree or five years of technical trade school is required.
  • Experience developing and maintaining instrument indices, input/output lists, and datasheets is required.
  • Working knowledge of Rockwell Automation programmable logic controller/human-machine interface systems and Yokogawa or other distributed control systems is required.
  • Experience with industrial communication networks is required.
  • Ability to work independently with little to no direction and take initiative within the scope of work responsibilities is required.
  • Effective written and oral communication skills are required.
  • Technical proficiency, organizational skills, and time-management skills are required.
  • Ability to manage multiple projects is required.
  • Working knowledge of the National Electrical Code and electrical installation and mechanical practices is required.
  • Ability to work safely in indoor and outdoor production environments, including environments containing hazardous elements, and comply with safety policies, standard operating procedures, batch production records, and applicable International Organization for Standardization standards is required.
  • Ability to sit for at least six hours per day, stand, walk, bend, reach overhead, occasionally lift or carry up to 50 pounds, perform repetitive hand and arm use for writing and computer work, climb ladders, and work at heights is required.
Responsibilities
  • Develop instrument indices, input/output lists, instrument datasheets, and similar documentation using an instrument database or similar tool.
  • Assist in selecting instrumentation for process-control applications.
  • Assist with instrument-sizing calculations for valves, flowmeters, and similar equipment.
  • Assist process engineers and other disciplines with process and instrumentation diagram development.
  • Develop control-system network drawings.
  • Develop or modify programmable logic controller/human-machine interface or distributed control system applications as required.
  • Coordinate with other disciplines to locate control panels and ensure appropriate control power and utilities are provided for instrumentation and control devices and panels.
  • Provide instrumentation and control and automation feedback for process requirements involving process and mechanical equipment.
  • Develop instrumentation and control and automation construction specifications as required.
  • Manage projects from start to finish to support the maintenance electrical and instrumentation department with training, project documentation, and drawings.
  • Mentor electrical and instrumentation technicians, automation specialists, control technicians, and onsite maintenance contractors as required.
  • Work with original equipment manufacturers and engineering firms to create control-panel drawings and review them for accuracy and compliance with specification requirements.
  • Perform maintenance and upgrades on existing control systems and industrial communication networks.
  • Provide rotating on-call coverage for automation issues.
Desired Qualifications
  • Project management skills are a plus.
Ajinomoto Health & Nutrition North America

Ajinomoto Health & Nutrition North America

View

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • June 22, 2026 Syntax Bio collaboration broadens StemFit into cell-therapy development.
  • June 4, 2025 Raleigh lab renovation upgraded analytics, workflow, and safety.
  • June 23, 2025 Salt Answer and Palate Perfect target sodium reduction and formulation wins.

What critics are saying

  • Akron's roughly $14.5 million expansion depends on 2025 city negotiations and December 2026 completion.
  • StemFit's commercial value still depends on Syntax Bio validation, not revenue.
  • If fermented flavor platforms stall, AHN remains trapped in commodity amino-acid pricing.

What makes Ajinomoto Health & Nutrition North America unique

  • Ajinomoto's amino-acid science spans food, pharma, nutraceutical, and cell-culture applications.
  • StemFit chemically defined media supports reproducible stem-cell workflows for regenerative medicine.
  • Salt Answer and Palate Perfect use proprietary umami, kokumi, and fermentation technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Holidays

Parental Leave

Flexible Work Hours

Wellness Program

Life Insurance

Disability Insurance

Tuition Reimbursement

Mental Health Support

Professional Development Budget

Company News

Business Wire
Jun 22nd, 2026
Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. collaborate to evaluate stem cell culture technologies using Cellgorithm(TM) platform.

Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. collaborate to evaluate stem cell culture technologies using Cellgorithm(TM) platform. The collaboration will evaluate Ajinomoto Group's stem cell culture products using Syntax Bio's programmable stem cell differentiation platform to support improved regenerative medicine discovery, development, and manufacturing. CHICAGO & ITASCA, Ill.-(BUSINESS WIRE)-Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture innovation and part of Ajinomoto Group, today announced a collaboration to evaluate Ajinomoto Group's StemFit(TM) stem cell culture products using Syntax Bio's proprietary Cellgorithm(TM) platform. Syntax Bio and Ajinomoto Health & Nutrition North America are collaborating to evaluate stem cell culture technologies that could enhance the performance, consistency and scalability of regenerative medicine discovery, development and manufacturing. Share Through the collaboration, AHN is providing Syntax Bio with StemFit(TM) stem cell culture media products to demonstrate Cellgorithm(TM) compatibility, performance and workflow optimization. Syntax Bio will evaluate StemFit(TM) and generate data to support their growing pipeline of cell therapy collaborations. "We are excited to support Syntax Bio's innovative approach to stem cell differentiation," said Michael Lish, President & CEO of Ajinomoto Health & Nutrition North America, Inc. "StemFit(TM) provides a highly controlled and reliable culture environment that is well-suited to complement advanced platforms like Cellgorithm(TM). By supporting a smooth transition from research workflows and potentially toward manufacturing applications, we believe our solutions can help accelerate the development of next-generation cell therapies." "The development of cell therapies depends on having compatible and reproducible technologies across every stage of the workflow, including the environments used to grow and maintain cells," said John Craighead, Ph.D., CEO of Syntax Bio. "Collaborating with Ajinomoto Group gives us the opportunity to evaluate high-performance stem cell culture products using our Cellgorithm(TM) platform to enhance efficiency, consistency, and scale across many regenerative medicine applications." Cellgorithm(TM) technology simplifies stem cell differentiation by programming the sequence of gene activations needed to create specific cell types. The platform reduces the need for repeated manual interventions and has demonstrated the ability to generate target cell types in days or weeks rather than months. Through collaborations with innovators such as Syntax Bio, Ajinomoto Group aims to explore expanding the use of StemFit(TM) into more advanced cell development and potential future manufacturing processes. This initiative supports the company's broader goal of advancing regenerative medicine with high-quality solutions that improve reliability, safety, and scalability across cell therapy development and production. About Syntax Bio Syntax Bio is a synthetic biology company programming the next generation of cell therapies. Its proprietary Cellgorithm(TM) platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how regenerative medicines are discovered, developed, and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio makes cellular generation more reliable and scalable at unprecedented speed, unlocking new possibilities across the biotechnology industry. Learn more at www.syntaxbio.com. About Ajinomoto Health & Nutrition North America, Inc. Ajinomoto Health & Nutrition North America, Inc. is a wholly-owned subsidiary of Ajinomoto Group, a global leader in amino acid science and the research, development, manufacture, and sale of amino acid-based products across pharmaceutical, nutraceutical, sports nutrition, health and beauty, and food industries. Building on its long-standing expertise in amino acid technologies, the company is advancing regenerative medicine by providing high-quality, chemically defined stem cell culture media, including the StemFit(TM) series, which supports the development of safe, reliable, and scalable cell therapies. For additional information, please visit www.ajihealthandnutrition.com. Contacts. Ajinomoto Health & Nutrition North America, Inc. Kimberly Kennedy [email protected] More News From Syntax Bio CHICAGO-( BUSINESS WIRE )-Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio's Series A to $14.4 million and total funding to over $25 million. The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansu... CHICAGO-( BUSINESS WIRE )-Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes. Under the collaboration, the teams seek to define and develop an allogeneic pancreatic beta cell therapy for insulin-dependent diabetes based on patient needs. Syntax Bio plans to use its proprietary CellgorithmTM platform to gui... CHICAGO & NEW YORK-( BUSINESS WIRE )-Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, under its Industry Discovery and Development Partnership (IDDP) program to advance a pancreatic beta cell therapy targeting T1D using its Cellgorithm platform technology. "The daily burden for those living with t...

PR Newswire
Jun 4th, 2025
Ajinomoto Health Nutrition North America, Inc. Opens Quality Control Laboratory Following $2.1M Renovation

RALEIGH, N.C., June 4, 2025 /PRNewswire/ -- Ajinomoto Health & Nutrition North America, Inc. (AHN), a global leader in amino acid manufacturing, celebrated the opening of its renovated Quality Control Laboratory today with a ribbon-cutting ceremony.Global senior leaders and dedicated team members who have been integral to the renovation efforts gathered at the modern facility on AHN's Raleigh, North Carolina, campus. The re-envisioned lab showcases AHN's commitment to delivering top product quality and leading safety standards."By updating our facilities, we are even more equipped to meet the evolving needs of our customers and maintain our position as a leader in the industry," said Jessica Lee, Quality Manager. "Our Quality Control Laboratory is part of Ajinomoto Health and Nutrition's ongoing investment in quality and innovation."With the expanding need for amino acids in today's market, AHN's Quality Control Laboratory features advanced analytical equipment, improved workflow efficiencies, and enhanced safety measures. The facility benefits from Raleigh's skilled workforce, top universities, and numerous life sciences support companies, strengthening the area's reputation as a leading biotech hub.The enhancements also support AHN's growth plan for supplying Active Pharmaceutical Ingredient (API) amino acids and blends globally.By investing in these upgrades, AHN is positioning itself to meet the increasing global demand for high-quality APIs. The improved laboratory enables AHN to scale production and maintain stringent quality standards across larger volumes

PR Newswire
Feb 11th, 2025
Ajinomoto Co., Inc., Through Its Subsidiary Ajinomoto Health Nutrition North America, Inc., Announces Gold Sponsorship Of Labcentral: Accelerating Innovation In Biotechnology

CAMBRIDGE, Mass., Feb. 11, 2025 /PRNewswire/ -- Ajinomoto Co., Inc., a global leader in biotechnology and food innovation, proudly announces its sponsorship of LabCentral, a premier launchpad for high-potential life sciences and biotech startups located in the heart of the Greater Boston biotechnology community. This partnership underscores the Ajinomoto Group's commitment to fostering innovation, collaboration, and scientific advancement in this rapidly evolving sector and thriving ecosystem.The sponsorship is in full alignment with the Ajinomoto Group's purpose to contribute to the well-being of all human beings, our society, and our planet with "AminoScience" and its cutting-edge technologies, including innovations in cell and gene therapy, amino acid, and protein sciences. The Ajinomoto Innovation Strategy Development Team in particular is fully committed to supporting the thriving biotech ecosystem in Cambridge and Massachusetts.LabCentral, located in Cambridge, provides startups with the laboratory space, resources, and community necessary to translate breakthrough ideas into viable solutions. The Ajinomoto Group's sponsorship will enhance LabCentral's ability to support promising ventures in areas such as drug discovery, cell and gene therapy, and other transformative life sciences fields."LabCentral represents the nexus of innovation and opportunity in biotech, and the Ajinomoto Group is honored to support its mission of empowering next-generation startups," said Dr. Ikuo Kira, Executive Officer & Vice President, General Manager, North America Division

AgFunder
Jul 31st, 2024
Shiru And Ajinomoto Team Up On Ai-Powered Sweet Protein Discovery Journey

Protein discovery startup Shiru has teamed up with Ajinomoto Health Nutrition Partners, part of ingredients giant Ajinomoto, to develop and commercialize sweet proteins: high intensity natural sweeteners that can replace sugar in beverages and other products. Natural sweeteners such as stevia and monk fruit have improved significantly in recent years. However, sweet proteins—which are found in fruits and berries that grow near the equator and can be up to 5,000x sweeter than sugar with no impact on blood glucose—add an exciting new dimension to the natural sugar-reduction toolbox, Shiru founder and CEO Dr. Jasmin Hume told AgFunderNews. The challenge, she says, has been two-fold. First, identifying proteins in nature with the right kind of sweetness (without linger, stability issues, etc)

vegconom GmbH
Jul 31st, 2024
Shiru and Ajinomoto Health & Nutrition Partner to Develop Sweet Proteins That Can Replace Sugar

Shiru and Ajinomoto Health & Nutrition partner to develop sweet proteins that can replace sugar.